The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVZM.Y | +23.3% | +26.49% | +4.81% | +1,792% |
| S&P | +18.55% | +83.81% | +12.95% | +732% |
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.24B | 0.0% |
| Gross Profit | $635.69M | 0.0% |
| Gross Margin | 51.08% | 0.0% |
| Market Cap | $25.18B | 0.0% |
| Net Income | $161.26M | 0.0% |
| EBITDA | $399.99M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $330.53M | 0.0% |
| Accounts Receivable | $867.27M | 0.0% |
| Inventory | 871.9 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.30B | 0.0% |
| Short Term Debt | $356.03M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | 15.43% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $430.80M | 0.0% |
| Operating Free Cash Flow | $542.85M | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|
| Price to Book | 2.08 | 2.75 | 2.26 | - |
| Price to Tangible Book Value | 20.20 | 20.21 | -46.19 | - |
| Enterprise Value to EBITDA | 66.05 | 92.19 | 79.53 | - |
| Total Debt | $1.84B | $3.90B | $3.65B | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
